Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
Philip J. Mease, Gülen Hatemi, Maria Paris, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 809-820
Open Access | Times Cited: 18

Showing 18 citing articles:

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, et al.
Dermatology and Therapy (2025)
Open Access | Times Cited: 2
High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Kave Shams, Jennifer Montgomery, J. E. Morley, et al.
Dermatology and Therapy (2025)
Open Access
Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease
Piotr Kawczak, Igor Feszak, Tomasz Bączek
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2605-2605
Open Access
Is Safety Profile of Apremilast in Elderly Patients Same With That in Young and Middle‐Aged Patients? A Real‐World Disproportionality Analysis of the FDA Adverse Event Reporting System
Chenyang Yu, Jinxin Qi, Wei Yan, et al.
Dermatologic Therapy (2025) Vol. 2025, Iss. 1
Open Access
Real-World Effectiveness and Tolerability of Apremilast in Psoriatic Arthritis in Germany: Results from LAPIS-PsA
Frank Behrens, J. Wollenhaupt, Michael Fiene, et al.
The Open Rheumatology Journal (2025) Vol. 19, Iss. 1
Open Access
Letter by Gu et al Regarding Article, “Antisense Oligonucleotide Therapy for Calmodulinopathy”
Siyuan Gu, Ye Chen, Xiaojian Shi
Circulation (2025) Vol. 151, Iss. 18
Closed Access
Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
Y. Xu, X LIU, Linghong Guo, et al.
Clinical Cosmetic and Investigational Dermatology (2025) Vol. Volume 18, pp. 1121-1135
Open Access
The efficacy of apremilast in pemphigus: a systematic review of case reports
Roudin Alhasawi, Esraa A. Shaheen, Noura Mohammed Alshabanat, et al.
Dermatology Reports (2025)
Open Access
PDE4 inhibitors in psoriasis therapy: current insights and future directions
Amit Sharma, Niyati Pandoh, Keerti Dayal, et al.
Inflammopharmacology (2025)
Closed Access
Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study
Mamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 7, pp. 950-963
Open Access | Times Cited: 3
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Laure Gossec, Laura C. Coates, Dafna D. Gladman, et al.
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 11, pp. 1480-1488
Open Access | Times Cited: 3
Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy
Karmela Kim Chan, Anne R. Bass
Rheumatic Disease Clinics of North America (2024) Vol. 50, Iss. 2, pp. 337-357
Closed Access | Times Cited: 2
Diabetes and obesity burden and improvements in cardiometabolic parameters in patients with psoriasis or psoriatic arthritis receiving apremilast in a real-world setting
Cristi Cavanaugh, Kate K. Orroth, Xi Qian, et al.
JAAD International (2024) Vol. 16, pp. 244-251
Open Access | Times Cited: 2
GRAPPA Debate: Targeted Small Molecules Versus Biologics as First-Line Systemic Therapy After Conventional Therapy for Moderate-to-Severe Psoriasis
Wilson Liao, April W. Armstrong, Kristina Callis Duffin
The Journal of Rheumatology (2024) Vol. 51, Iss. Suppl 2, pp. 89-92
Closed Access | Times Cited: 2
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3778-3791
Closed Access | Times Cited: 2
Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study
Mikkel Østergaard, Mikael Boesen, Walter P. Maksymowych, et al.
The Lancet Rheumatology (2024)
Closed Access | Times Cited: 2
Severe Electrolyte Abnormalities and Distal Renal Tubular Acidosis in the Setting of Apremilast Use for Psoriatic Arthritis: A Case Report
Brody M Fogleman, Emilie T. McKinnon, Schuyler Nebeker, et al.
Cureus (2024)
Open Access | Times Cited: 1
Disease and Treatment-Specific Complications of Behçet Syndrome
Sinem Nihal Esatoğlu, Yeşim Özgüler, Gülen Hatemi
Current Rheumatology Reports (2023) Vol. 26, Iss. 1, pp. 1-11
Closed Access | Times Cited: 3
Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands
J.M.P.A. van den Reek, R.J.T. van der Leest, Sarah E. Thomas, et al.
Advances in Therapy (2024) Vol. 41, Iss. 4, pp. 1594-1605
Closed Access
Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review
Carrie A Forman, Shari R. Lipner
Indian Dermatology Online Journal (2024) Vol. 16, Iss. 1, pp. 50-58
Open Access
The Use of Biologic and Targeted Synthetic Disease-Modifying Drugs in the Treatment of Psoriatic Arthritis
Ruqaya Mustafa Ali, Arthur Lau, Lawrence H. Brent
Biologics (2024) Vol. 5, Iss. 1, pp. 1-1
Open Access
New and future perspectives in Behçet's syndrome
Berçemhan Sulu, Gülen Hatemi
Archives of Rheumatology (2024) Vol. 39, Iss. 4, pp. 511-521
Open Access
Page 1

Scroll to top